Femke A I Ehlers

Defucosylation of Tumor-Specific Humanized Anti-MUC1 Monoclonal Antibody Enhances NK Cell-Mediated Anti-Tumor Cell Cytotoxicity

W. Germeraad, Roel G J Klein Wolterink, G. Bos, 2021, Cancers.

ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response

L. Kooreman, M. Smidt, G. Bos, 2021, Cancers.

Activated Natural Killer Cells Withstand the Relatively Low Glucose Concentrations Found in the Bone Marrow of Multiple Myeloma Patients

G. Bos, L. Wieten, Femke A I Ehlers, 2021, Frontiers in Oncology.

Polymorphic differences within HLA‐C alleles contribute to alternatively spliced transcripts lacking exon 5

M. Tilanus, C. Voorter, G. Bos, 2022, HLA.

Tuning Natural Killer Cell Anti-multiple Myeloma Reactivity by Targeting Inhibitory Signaling via KIR and NKG2A

G. Bos, L. Wieten, Femke A I Ehlers, 2018, Front. Immunol..

Inhibitory receptors for HLA class I as immune checkpoints for natural killer cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy

G. Bos, L. Wieten, Femke A I Ehlers, 2022, Cancer Immunology, Immunotherapy.

NKG2A Expression Is Not per se Detrimental for the Anti-Multiple Myeloma Activity of Activated Natural Killer Cells in an In Vitro System Mimicking the Tumor Microenvironment

M. Tilanus, G. Bos, L. Wieten, 2018, Front. Immunol..

Exploring the potential of combining IL-2-activated NK cells with an anti-PDL1 monoclonal antibody to target multiple myeloma-associated macrophages

G. Bos, L. Wieten, Femke A I Ehlers, 2023, Cancer Immunology, Immunotherapy.

NK cells in human visceral adipose tissue contribute to obesity‐associated insulin resistance through low‐grade inflammation

C. Stehouwer, C. V. D. van der Kallen, C. Schalkwijk, 2020, Clinical and translational medicine.